Elevation Oncology, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELEV research report →
Companyelevationoncology.com
Elevation Oncology, Inc. , a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion.
- CEO
- Joseph J. Ferra Jr.
- IPO
- 2021
- Employees
- 34
- HQ
- Boston, NY, US
Price Chart
Valuation
- Market Cap
- $21.63M
- P/E
- -0.88
- P/S
- 569.14
- P/B
- 0.46
- EV/EBITDA
- 0.32
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 36.84%
- Op Margin
- -65415.79%
- Net Margin
- -64860.53%
- ROE
- -46.17%
- ROIC
- -31.87%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-44,485,000 · 2.67%
- EPS
- $-0.78 · 41.79%
- Op Income
- $-44,703,000
- FCF YoY
- 35.27%
Performance & Tape
- 52W High
- $3.09
- 52W Low
- $0.22
- 50D MA
- $0.35
- 200D MA
- $0.49
- Beta
- 1.50
- Avg Volume
- 1.35M
Get TickerSpark's AI analysis on ELEV
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 23, 25 | Sandler Alan B. | sell | 35,000 |
| Jul 23, 25 | Sandler Alan B. | sell | 55,000 |
| Jul 23, 25 | Sandler Alan B. | sell | 35,000 |
| Jul 23, 25 | Mootz Darcy | sell | 55,000 |
| Jul 23, 25 | Mootz Darcy | sell | 35,000 |
| Jul 23, 25 | Mootz Darcy | sell | 35,000 |
| Jul 23, 25 | ELMS STEVE | sell | 35,000 |
| Jul 23, 25 | ELMS STEVE | sell | 35,000 |
| Jul 23, 25 | ELMS STEVE | sell | 31,238 |
| Jul 23, 25 | ELMS STEVE | sell | 15,619 |
Our ELEV Coverage
We haven't published any research on ELEV yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ELEV Report →